LIVIVO - Search results -

Search results

Result 1 - 10 of total 255

Search options

Book ; Online: Mariano Esteban, investigador de la vacuna del coronavirus

Esteban, Mariano

"La naturaleza no se domina con tanques y aviones"

2020

Abstract: El virólogo Mariano Esteban busca una vacuna contra el coronavirus causante de la Covid-19 desde su larga experiencia luchando contra estos “bichitos” que nos hacen tan vulnerables, porque la naturaleza no se domina con tanques y aviones, sino con armas ... ...

Abstract	El virólogo Mariano Esteban busca una vacuna contra el coronavirus causante de la Covid-19 desde su larga experiencia luchando contra estos “bichitos” que nos hacen tan vulnerables, porque la naturaleza no se domina con tanques y aviones, sino con armas muy pequeñas y específicas. Director del grupo Poxvirus y Vacunas del Centro Nacional de Biotecnología (CNB) del CSIC, Esteban dice que del SARS-Cov-2 ha sorprendido su capacidad de contagio y cree que en el futuro habrá ciclos en los que reaparezca, pero se actuará más rápido y se conseguirá abortar su proceso de extensión. No
Keywords	covid19
Language	Spanish
Publishing date	2020-04-13
Publisher	Mediaset España Comunicación
Publishing country	es
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.

Gómez, Carmen Elena / Perdiguero, Beatriz / Esteban, Mariano

Vaccines

2021 Volume 9, Issue 3

Abstract: The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants in different continents is causing a major concern in human global health. These variants have in common a higher transmissibility, becoming dominant within ... ...

Abstract	The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants in different continents is causing a major concern in human global health. These variants have in common a higher transmissibility, becoming dominant within populations in a short time, and an accumulation of a high number of mutations in the spike (S) protein, especially within the amino terminal domain (NTD) and the receptor binding domain (RBD). These mutations have direct implications on virus infection rates through higher affinity of S RBD for the cellular angiotensin-converting enzyme-2 (ACE-2) receptor. There are also signs of enhanced virulence, re-infection frequency, and increased resistance to the action of monoclonal and polyclonal antibodies from convalescence sera and in vaccinated individuals in regions where the variants spread dominantly. In this review, we describe the different SARS-CoV-2 variants that have thus far been identified in various parts of the world with mutational changes and biological properties as well as their impact in medical countermeasures and human health.
Language	English
Publishing date	2021-03-11
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines9030243
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus.

García-Arriaza, Juan / Esteban, Mariano / López, Daniel

Biomedicines

2021 Volume 9, Issue 9

Abstract: There is a need to develop a highly effective vaccine against the emerging chikungunya virus (CHIKV), a mosquito- ... ...

Abstract	There is a need to develop a highly effective vaccine against the emerging chikungunya virus (CHIKV), a mosquito-borne
Language	English
Publishing date	2021-08-31
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2720867-9
ISSN	2227-9059
ISSN	2227-9059
DOI	10.3390/biomedicines9091122
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy.

Lennol, Matthew P / García-Ayllón, María-Salud / Esteban, Mariano / García-Arriaza, Juan / Sáez-Valero, Javier

Frontiers in immunology

2022 Volume 13, Page(s) 1001951

Abstract: Various species of the SARS-CoV-2 host cell receptor, the angiotensin-converting enzyme 2 (ACE2), are present in serum, which may result from virus entry and subsequent proteolytic processing of the membrane receptor. We have recently demonstrated ... ...

Abstract	Various species of the SARS-CoV-2 host cell receptor, the angiotensin-converting enzyme 2 (ACE2), are present in serum, which may result from virus entry and subsequent proteolytic processing of the membrane receptor. We have recently demonstrated changes of particular ACE2 species in virus infected humans, either cleaved fragments or circulating full-length species. Here, we further explore the potential of serum ACE2 as a biomarker to test SARS-CoV-2 infection and vaccine efficacy in virus susceptible transgenic K18-hACE2 mice expressing human ACE2. First, in serum samples derived from K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2, we observed an increase in the levels of cleaved ACE2 fragment at day 2 post-challenge, which may represent the subsequent proteolytic processing through virus entry. These elevated levels were maintained until the death of the animals at day 6 post-challenge. The circulating full-length ACE2 form displayed a sizable peak at day 4, which declined at day 6 post-challenge. Noticeably, immunization with two doses of the MVA-CoV2-S vaccine candidate prevented ACE2 cleaved changes in serum of animals challenged with a lethal dose of SARS-CoV-2. The efficacy of the MVA-CoV2-S was extended to vaccinated mice after virus re-challenge. These findings highlight that ACE2 could be a potential serum biomarker for disease progression and vaccination against SARS-CoV-2.
MeSH term(s)	Animals ; Humans ; Mice ; Angiotensin-Converting Enzyme 2 ; Biomarkers ; COVID-19/prevention & control ; Mice, Transgenic ; Peptidyl-Dipeptidase A/genetics ; Peptidyl-Dipeptidase A/metabolism ; SARS-CoV-2 ; Vaccine Efficacy
Chemical Substances	Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) ; Biomarkers ; K-18 conjugate ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23)
Language	English
Publishing date	2022-10-12
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.1001951
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.

Esteban, Mariano

Human vaccines

2009 Volume 5, Issue 12, Page(s) 867–871

Abstract: As yet, the only human infectious disease eradicated from our planet is smallpox, caused by variola virus a member of the poxvirus family. The vaccination success, with the declaration by WHO in 1980 of a worldwide free of smallpox, was largely due to ... ...

Abstract	As yet, the only human infectious disease eradicated from our planet is smallpox, caused by variola virus a member of the poxvirus family. The vaccination success, with the declaration by WHO in 1980 of a worldwide free of smallpox, was largely due to the availability of a quite effective and stable live vaccine, as well as the restricted human host for virus infection. Variola was considered one of the most devastating diseases of human mankind. With the sudden appearance of the HIV/AIDS in 1981, an infection which spread rapidly to become a pandemic in a short time, causing up to date more than 22 million deaths, about 40 million people infected and a current incidence of about 3 million deaths per year, this dreadful pandemic has become one of the most severe diseases in the World, specially in poor countries. While different antiviral drugs have been developed that block virus replication at various stages of infection, however the rapid virus escape that follows during the drug therapy due to mutations, makes the development of vaccines the most secure option to control and eradicate the disease. Numerous vaccines have been developed, but to date the clinical trials have failed to show any efficacy against HIV infection. Due to the proven success of vaccinia virus in the control of smallpox as well as of poxvirus recombinants against veterinary diseases, a major effort has been directed to document the advantages of poxvirus vectors as vaccines against multiple diseases. Two of the most promising poxvirus vectors are the highly attenuated modified vaccinia virus Ankara (MVA) and the modified Copenhagen strain NYVAC. In this commentary I describe the biological characteristics of the attenuated poxvirus vectors, MVA and NYVAC, with emphasis in their application in HIV preclinical and clinical trials, and considerations as future HIV vaccines.
MeSH term(s)	AIDS Vaccines/genetics ; AIDS Vaccines/immunology ; Genetic Vectors ; HIV Infections/prevention & control ; Humans ; Vaccinia virus/genetics ; Vaccinia virus/growth & development ; Vaccinia virus/immunology ; Vaccinia virus/pathogenicity
Chemical Substances	AIDS Vaccines
Language	English
Publishing date	2009-12-03
Publishing country	United States
Document type	Journal Article ; Review
ISSN	1554-8619
ISSN (online)	1554-8619
DOI	10.4161/hv.9693
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Bioluminescence Imaging as a Tool for Poxvirus Biology.

Perdiguero, Beatriz / Gómez, Carmen Elena / Esteban, Mariano

Methods in molecular biology (Clifton, N.J.)

2019 Volume 2023, Page(s) 269–285

Abstract: Bioluminescence imaging, with luciferase as a reporter-encoding gene, has been successfully and widely used for studies to follow viral infection in an organism and to measure therapeutic efficacy of antiviral agents in small animal models. ... ...

Abstract	Bioluminescence imaging, with luciferase as a reporter-encoding gene, has been successfully and widely used for studies to follow viral infection in an organism and to measure therapeutic efficacy of antiviral agents in small animal models. Bioluminescence is produced by the reaction of a luciferase enzyme stably inserted into the viral genome with a defined substrate systemically delivered into the animal. The light emitted is captured allowing the detection of viral infection sites and the quantification of viral replication in the context of tissues of a living animal. The goal of this chapter is to provide a technical background for the evaluation of poxvirus infection in cells and animals through bioluminescence imaging technology using luciferase-expressing recombinant poxviruses.
MeSH term(s)	Animals ; Antiviral Agents/pharmacology ; Humans ; Luminescent Measurements/methods ; Poxviridae/drug effects ; Poxviridae/genetics ; Virus Diseases/prevention & control
Chemical Substances	Antiviral Agents
Language	English
Publishing date	2019-06-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1940-6029
ISSN (online)	1940-6029
DOI	10.1007/978-1-4939-9593-6_17
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Hepatitis C and evasion of the interferon system: a PKR paradigm.

Esteban, Mariano

Cell host & microbe

2009 Volume 6, Issue 6, Page(s) 495–497

Abstract: Hepatitis C virus (HCV) is resistant to the antiviral cytokine type I interferon, representing a major clinical problem. Garaigorta and Chisari (2009) reveal that HCV uses the activation of the ds-RNA-dependent protein kinase R, which phosphorylates and ... ...

Abstract	Hepatitis C virus (HCV) is resistant to the antiviral cytokine type I interferon, representing a major clinical problem. Garaigorta and Chisari (2009) reveal that HCV uses the activation of the ds-RNA-dependent protein kinase R, which phosphorylates and inhibits the translation initiation factor eIF-2 alpha, to block translation of interferon-stimulated genes.
MeSH term(s)	Hepacivirus/physiology ; Hepatitis C/enzymology ; Hepatitis C/genetics ; Hepatitis C/metabolism ; Hepatitis C/virology ; Humans ; Interferon Regulatory Factors/genetics ; Interferon Regulatory Factors/metabolism ; Interferon Type I/metabolism ; Phosphorylation ; eIF-2 Kinase/genetics ; eIF-2 Kinase/metabolism
Chemical Substances	Interferon Regulatory Factors ; Interferon Type I ; eIF-2 Kinase (EC 2.7.11.1)
Language	English
Publishing date	2009-12-14
Publishing country	United States
Document type	Comment ; Journal Article
ZDB-ID	2278004-X
ISSN	1934-6069 ; 1931-3128
ISSN (online)	1934-6069
ISSN	1931-3128
DOI	10.1016/j.chom.2009.11.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers.

Álvarez, Enrique / Falqui, Michela / Sin, Laura / McGrail, Joseph Patrick / Perdiguero, Beatriz / Coloma, Rocío / Marcos-Villar, Laura / Tárrega, Céline / Esteban, Mariano / Gómez, Carmen Elena / Guerra, Susana

Vaccines

2024 Volume 12, Issue 2

Abstract: The Interferon Stimulated Gene 15 (ISG15), a unique Ubiquitin-like (Ubl) modifier exclusive to vertebrates, plays a crucial role in the immune system. Primarily induced by interferon (IFN) type I, ISG15 functions through diverse mechanisms: (i) covalent ... ...

Abstract	The Interferon Stimulated Gene 15 (ISG15), a unique Ubiquitin-like (Ubl) modifier exclusive to vertebrates, plays a crucial role in the immune system. Primarily induced by interferon (IFN) type I, ISG15 functions through diverse mechanisms: (i) covalent protein modification (ISGylation); (ii) non-covalent intracellular action; and (iii) exerting extracellular cytokine activity. These various roles highlight its versatility in influencing numerous cellular pathways, encompassing DNA damage response, autophagy, antiviral response, and cancer-related processes, among others. The well-established antiviral effects of ISGylation contrast with its intriguing dual role in cancer, exhibiting both suppressive and promoting effects depending on the tumour type. The multifaceted functions of ISG15 extend beyond intracellular processes to extracellular cytokine signalling, influencing immune response, chemotaxis, and anti-tumour effects. Moreover, ISG15 emerges as a promising adjuvant in vaccine development, enhancing immune responses against viral antigens and demonstrating efficacy in cancer models. As a therapeutic target in cancer treatment, ISG15 exhibits a double-edged nature, promoting or suppressing oncogenesis depending on the tumour context. This review aims to contribute to future studies exploring the role of ISG15 in immune modulation and cancer therapy, potentially paving the way for the development of novel therapeutic interventions, vaccine development, and precision medicine.
Language	English
Publishing date	2024-02-01
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines12020153
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Neutrophil and vaccine.

Di Pilato, Mauro / Esteban, Mariano

Cell cycle (Georgetown, Tex.)

2015 Volume 14, Issue 11, Page(s) 1615–1616

MeSH term(s)	Animals ; Antigen-Presenting Cells/immunology ; Cell Movement/immunology ; Cell Polarity/immunology ; Gene Expression Regulation/immunology ; Granulocyte-Macrophage Colony-Stimulating Factor/immunology ; Humans ; Mice ; Models, Immunological ; Neutrophils/immunology ; Transforming Growth Factor beta/immunology
Chemical Substances	Transforming Growth Factor beta ; Granulocyte-Macrophage Colony-Stimulating Factor (83869-56-1)
Language	English
Publishing date	2015-04-28
Publishing country	United States
Document type	Editorial
ZDB-ID	2146183-1
ISSN	1551-4005 ; 1538-4101 ; 1554-8627
ISSN (online)	1551-4005
ISSN	1538-4101 ; 1554-8627
DOI	10.1080/15384101.2015.1039362
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5881: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Enhancing poxvirus vectors vaccine immunogenicity.

García-Arriaza, Juan / Esteban, Mariano

Human vaccines & immunotherapeutics

2014 Volume 10, Issue 8, Page(s) 2235–2244

Abstract: Attenuated recombinant poxvirus vectors expressing heterologous antigens from pathogens are currently at various stages in clinical trials with the aim to establish their efficacy. This is because these vectors have shown excellent safety profiles, ... ...

Abstract	Attenuated recombinant poxvirus vectors expressing heterologous antigens from pathogens are currently at various stages in clinical trials with the aim to establish their efficacy. This is because these vectors have shown excellent safety profiles, significant immunogenicity against foreign expressed antigens and are able to induce protective immune responses. In view of the limited efficacy triggered by some poxvirus strains used in clinical trials (i.e, ALVAC in the RV144 phase III clinical trial for HIV), and of the restrictive replication capacity of the highly attenuated vectors like MVA and NYVAC, there is a consensus that further improvements of these vectors should be pursuit. In this review we considered several strategies that are currently being implemented, as well as new approaches, to improve the immunogenicity of the poxvirus vectors. This includes heterologous prime/boost protocols, use of co-stimulatory molecules, deletion of viral immunomodulatory genes still present in the poxvirus genome, enhancing virus promoter strength, enhancing vector replication capacity, optimizing expression of foreign heterologous sequences, and the combined use of adjuvants. An optimized poxvirus vector triggering long-lasting immunity with a high protective efficacy against a selective disease should be sought.
MeSH term(s)	DNA Replication ; Drug Carriers ; Gene Expression ; Genetic Vectors ; Humans ; Poxviridae/genetics ; Vaccination/methods ; Vaccines, Attenuated/genetics ; Vaccines, Attenuated/immunology ; Vaccines, Synthetic/genetics ; Vaccines, Synthetic/immunology ; Viral Vaccines/genetics ; Viral Vaccines/immunology
Chemical Substances	Drug Carriers ; Vaccines, Attenuated ; Vaccines, Synthetic ; Viral Vaccines
Language	English
Publishing date	2014
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2664176-8
ISSN	2164-554X ; 2164-5515
ISSN (online)	2164-554X
ISSN	2164-5515
DOI	10.4161/hv.28974
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 6967: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito